Imaging-Guided Synergistic Photo-Chemotherapy Using Doxorubicin-Loaded Gadolinium Porphyrin-Based Metal–Organic Framework Nanosheets
Source abstract
Abstract
Porphyrin-based metal–organic framework (MOF) nanosheets have promising potential for drug loading and imaging-guided photodynamic therapy. However, the feasibility of performing imaging-guided three-channel photodynamic-photothermal-chemotherapy to treat cancer was seldom reported. The study showed that the gadolinium-porphyrin-based MOF nanosystem (DOX-Gd-TCPP) was constructed by loading doxorubicin (DOX) on the surface of tetrakis (4-carboxyphenyl) porphyrin (TCPP) with chelated gadolinium(III) ions. DOX-Gd-TCPP displayed superior drug loading capacity (up to 60%). Compared to separate photothermal, photodynamic, or chemotherapy, DOX-Gd-TCPP nanosheets showed significantly higher efficacy against cancer through the combination effect of three-channel therapeutic modalities. Meanwhile, DOX-Gd-TCPP nanosheets exhibited excellent fluorescence and magnetic resonance imaging capability. It is predicted that the imaging-guided synergistic photo-chemotherapy strategy suggests that DOX-Gd-TCPP MOF nanosheets could potentially be used in cancer theranostics technology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing210000, Jiangsu, China
Department of Urology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing210000, Jiangsu, China
Funding
Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China
References (36)
Show source-provided references
1. 10.3322/caac.2170810.3322/caac.21708 ↗
2. 10.1093/annonc/mdy19210.1093/annonc/mdy192 ↗
3. 10.1080/14737140.2020.173221110.1080/14737140.2020.1732211 ↗
4. 10.1016/j.cpet.2018.02.00610.1016/j.cpet.2018.02.006 ↗
5. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
6. 10.1016/j.biopha.2018.07.04910.1016/j.biopha.2018.07.049 ↗
7. 10.1002/ijc.3171710.1002/ijc.31717 ↗
8. 10.1002/adma.20120462310.1002/adma.201204623 ↗
9. 10.3390/pharmaceutics1402032210.3390/pharmaceutics14020322 ↗
10. 10.1186/s12951-022-01427-410.1186/s12951-022-01427-4 ↗
11. 10.3390/nano911154010.3390/nano9111540 ↗
12. 10.7150/thno.2772110.7150/thno.27721 ↗
13. 10.1021/la203883k10.1021/la203883k ↗
14. 10.3390/molecules2623726810.3390/molecules26237268 ↗
15. 10.1016/j.biomaterials.2019.11970710.1016/j.biomaterials.2019.119707 ↗
16. 10.1002/cnma.20170026410.1002/cnma.201700264 ↗
17. 10.3322/caac.2119910.3322/caac.21199 ↗
18. 10.1002/anie.20190988010.1002/anie.201909880 ↗
19. 10.1021/acsnano.9b0030010.1021/acsnano.9b00300 ↗
20. 10.7150/thno.2543310.7150/thno.25433 ↗
21. 10.1039/d1nr04489c10.1039/d1nr04489c ↗
22. 10.1039/d0bm01427c10.1039/d0bm01427c ↗
23. 10.1002/adma.20190233310.1002/adma.201902333 ↗
24. 10.1039/d1tb00358e10.1039/d1tb00358e ↗
25. 10.1016/j.bios.2016.06.01110.1016/j.bios.2016.06.011 ↗
26. 10.1093/nsr/nwaa22110.1093/nsr/nwaa221 ↗
27. 10.1021/acs.chemmater.8b0246710.1021/acs.chemmater.8b02467 ↗
28. 10.1039/d1tb00528f10.1039/d1tb00528f ↗
29. 10.1016/j.jcis.2021.11.01910.1016/j.jcis.2021.11.019 ↗
30. 10.1021/acsnano.6b0387410.1021/acsnano.6b03874 ↗
31. 10.1021/acsami.5b0102710.1021/acsami.5b01027 ↗
32. 10.1002/smll.20160345910.1002/smll.201603459 ↗
33. 10.1039/c9nr02463h10.1039/c9nr02463h ↗
34. 10.1021/acsnano.7b0775710.1021/acsnano.7b07757 ↗
35. 10.1039/c5dt04163e10.1039/c5dt04163e ↗
36. 10.1021/acsami.8b1904810.1021/acsami.8b19048 ↗